ReviewFrontiers in cell and developmental biology2026
Emerging biomaterials for osteomyelitis treatment: from material design to anti-infection and tissue regeneration.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteomyelitis (OM) is an infectious disease caused by the invasion of bone tissue by pathogenic microorganisms. It is frequently associated with biofilm formation, residual sequestra, local ischemia and hypoxia, elevated oxidative stress, and immune dysfunction. Conventional treatments rely on systemic antibiotics, surgical debridement, antibiotic-loaded bone cement, and bone transport techniques. Although these approaches can control infection in some cases, they remain limited by insufficient drug penetration, nondegradable materials, the need for secondary surgery, difficulty in repairing bone defects, and the risk of recurrence. In recent years, emerging biomaterials have provided new therapeutic strategies for OM by enabling the local delivery of antimicrobial agents, antimicrobial peptides, metal ions, or gaseous molecules, often in combination with photothermal therapy, sonodynamic therapy, pH/enzyme-responsive systems, and immunomodulation. The aim of this mini-review is to briefly summarize the pathological features of OM, outline the major design strategies of biomaterials currently used for OM treatment, and discuss the challenges associated with their clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.